Reading Time: 2 minutes
Medios (i.) was able to attract the attention of investors at the recent Capital Markets Day. With the "Medios Next Level" strategy, the company is transitioning to an integrated pharmaceutical service provider. For investors, this is a clear signal of focus. The division into the new segments Supply and Compounding is strategically sound. The trading business will primarily serve as a cash cow for liquidity assurance, while patient-specific manufacturing is set to be the central earnings driver to expand margins. Very interesting are the ambitions...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
